PRESS RELEASE

2004-06-08

Vitrolife receives FDA marketing approval of new products for the fastest growing market segments in ART (Assisted Reproductive Technology)

The American Food and Drug Administration (FDA) has given Vitrolife market clearance, 510(k), for G-FreezeKit Blast™, G-ThawKit Blast™, G-PGD™, and G-OOCYTE™. Cryopreservation of blastocysts and preimplantation genetic diagnosis (PGD) are both rapidly increasing infertility treatment procedures with high market potential and clear patient benefits.

G-FreezeKit Blast™ and G-ThawKit Blast™ are used for cryopreservation of human blastocysts, which could save women from multiple ovarian stimulation procedures and provide better pregnancy opportunities. Furthermore, cryopreservation of embryos using the GIII Series™ makes consecutive single embryo transfers possible thereby avoiding the risks associated with multiple pregnancies while maintaining good pregnancy rates.

G-PGD™ is developed to facilitate embryo biopsies. G-OOCYTE™ is used for handling of human eggs during intracytoplasmic sperm injection (ICSI). Both have new physiological compositions minimizing embryo stress from the environment.

The new products were developed in close collaboration with Dr. David K. Gardner and his research team at the Colorado Center for Reproductive Medicine.

"These new products represent a breakthrough as they help minimize embryo stress during ART procedures and we are happy to be able to offer these products to the clinics and patients in the USA", says Dr. Magnus Nilsson, President of Vitrolife.

"As there is an imminent need to reduce multiple pregnancies after IVF while maintaining effective infertility therapy, our new products address this need and offer real benefits to the patients", says Mr. Tony Winslöf, Marketing Director of Vitrolife.

New date for the six months report
The report previously announced for the 27th of August, 2004 will now be announced on the 17th of August, 2004.

Gothenburg, June 8, 2004.

Vitrolife AB (publ)

For further information, please contact;

CEO: Dr. Magnus Nilsson
Tel: +46 31 721 80 00
Mobile +46 708 22 80 61
mnilsson@vitrolife.com

Acting Marketing Director Tony Winslöf
Tel: +46 31 721 80 00
Mobile +46 708 22 80 15
twinslof@vitrolife.com

Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations focused on three geographic areas.

· Europe/Middle East
· The Americas
· Rest of the World

Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs.
